Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: Implications for internal radiotherapy with 90Y-DOTATOC

European Journal of Nuclear Medicine

Volumn 26, Issue 8, 1999, Pages 877-886

  Cremonesi, Marta ^a   Ferrari, Mahila ^a   Zoboli, Stefania ^a   Chinol, Marco ^a   Stabin, Michael G ^b   Orsi, Franco ^a   Maecke, Helmut R ^c   Jermann, Eduard ^c   Robertson, Christopher ^a   Fiorenza, Maurizio ^a   Tosi, Giampiero ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Nuclear Energy Department   (Brazil)

^c NONE

Author keywords

90Y 111In DOTATOC; Dosimetry; Peptides

Indexed keywords

DOTATOC; INDIUM 111; OCTREOTIDE[3 TYROSINE]; PHENYLALANINE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BLADDER; BLOOD; BONE MARROW; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARTMENT MODEL; DOSIMETRY; DRUG ABSORPTION; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY; KINETICS; LIVER; MEAN RESIDENCE TIME; RADIATION DOSE; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; URINALYSIS;

ADULT; AGED; HUMANS; INDIUM RADIOISOTOPES; MIDDLE AGED; OCTREOTIDE; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YTTRIUM RADIOISOTOPES;

EID: 0032764336     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050462     Document Type: Article

References (36)

1. 1. Reubi JC, Horisberger U, Lang W, et al. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumours. Am J Pathol 1989; 134: 337-344.
2. 2. Foekens JA, Portengen H, van Putten WLJ, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer 1989; 49: 7002-7009.
3. 3. Lipp RW, Silly H, Ranner G, et al. Radiolabelled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med 1995; 36: 13-18.
4. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
5. 5. Stolz B, Smith-Jones PM, Albert R, et al. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996; 57: 17-21.
6. 6. Krenning EP, Kooij PPM, Pauwels S, et al. Somatostatin receptor scintigraphy and radionuclide therapy. Digestion 1996; 57: 57-61.
7. 7. Lamberts SW, van der Lely AJ, De Herder WW, Holland L. Drug therapy - octreotide. N Engl J Med 1996; 334: 246-254.
8. 8. Hofland LJ, Lamberts SW. Somatostatin receptors and disease: role of receptor subtypes. Clin Endocrinol Metab 1996; 10: 163-176.
9. 9. Bruns C, Dietl MM, Palacios JM, Pless J. Identification and characterization of somatostatin receptors in neonatal rat long bones. Biochem J 1990; 265: 39-44.
10. 10. Otte A, Jennann E, Behe M, et al. DOTATOC - a new powerful tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-795.
11. 3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998; 75: 406-411.
12. 12. Macke, Béhé M, Froidevaux S, Heppler A, Jermann E. DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC): a unique somatostatin receptor ligand for labelling with a variety of metallic radionuclides. J Nucl Med 1997; 38: 18P.
13. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 1998; 25: 668-674.
14. 14. Otte A, Mueller-Brand J, Delias S, Nitzsche EU, Hermann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998; 351: 417-418.
15. 15. Béhé M, Heppeler A, Maecke HR. New somatostatin analogs for SPET and PET [abstract]. Eur J Nucl Med 1996; 23: 1144.
16. 16. Siegel J. Thomas S, Stubbs J. et al. Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. MIRD Pamphlet No. 16. J Nucl Med 1999; 40: S37-S61.
17. 17. Stabin MG, Kooij PPM, Bakker WH, et al. Radiation dosimetry for indium-111-pentredotide. J Nucl Med 1997; 38: 1919-1922.
18. 18. Foster D, Barret P. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. In: Proc. Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge Institute for Science and Education, 1998.
19. 19. Virgolini I, Szilvasi I, Kurtaran A, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumour patients. J Nucl Med 1998; 39: 1928-1936.
20. 20. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm 1990, vol. 3, No. 4.
21. 21. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 689-694.
22. 22. Trunnel JB, Duffy JB, Goodwin JT, et al: The distribution of radioactive iodine in human tissues: necropsy study in 9 patients. J Clin Endocrinol 1950; 10: 1007-1021.
23. 23. Thomas SR, Stabin MG, Chin-Tu C, et al. MIRD Pamphlet n. 14: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med 1992; 33: 783-802.
24. 24. Stabin MG. MIRDOSE: Personal computer software for intemal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
25. 25. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SW, Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography; relationship to EGF receptors. Int J Cancer 1990, 46: 416-420.
26. 26. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994; 35: 152-156.
27. 27. Krenning E, Kweekkeboom DJ, Pauels S, Kvols K, Reubi JC. Somatostatin receptors scintigraphy. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press; 1995: 1-45.
28. 28. Kooij PP, De Jong M, Boonzaaijer M, Krenning EP. The consequences of the effect of cold octreotide treatment on peptide receptor radionuclide therapy with [In-111-DTPA-D-Phe1]-octreotide. Eur J Nucl Med 1998; 25: 884.
29. 29. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephotoxicity of radiometal-labelled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the intemal radiation dosimetry. Cancer 1997; 80 (12 Suppl): 2591-2610.
30. 30. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993; 67: 1437-1439.
31. 31. Siegel. J. Stabin M, Sparks R, Brill R, and Breitz H. The MIRD method overestimates remainder of body dose to red marrow. J Nucl Med 1999; (under revision).
32. 32. De Jong M, Bakker VM, Krenning EP, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, D-Phe1,Tyr3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-371.
33. 33. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication 30. New York: Pergamon Press, 1979.
34. 90Y-biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999; 26: 110-120.
35. 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol 1991; 18: 469-476.
36. 36. The peptide way to macrocyclic bifunctional chelating agents: synthesis. Of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetra-acetic acid and study of its yttrium(III) complex. J Am Chem Soc 1988; 110: 6266-6267.